Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

[1]  G. Rogler,et al.  Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[2]  A. Luke,et al.  Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top‐Down” approach to intestinal fibrosis in mice , 2012, Inflammatory bowel diseases.

[3]  J. Rubin,et al.  Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. , 2011, Gastroenterology.

[4]  Jordi Rimola,et al.  Magnetic resonance imaging for evaluation of Crohn's disease: Validation of parameters of severity and quantitative index of activity , 2011, Inflammatory bowel diseases.

[5]  J. Gisbert,et al.  Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[6]  A. Cieza,et al.  Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health , 2011, Gut.

[7]  L. Peyrin-Biroulet.  Why should we define and target early Crohn's disease? , 2011, Gastroenterology & hepatology.

[8]  H. Hussain,et al.  Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. , 2011, Radiology.

[9]  L. Peyrin-Biroulet,et al.  Long‐term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population‐based cohorts , 2011, Inflammatory bowel diseases.

[10]  H. Tilg,et al.  Development of the Crohn's disease digestive damage score, the Lémann score , 2010, Inflammatory bowel diseases.

[11]  B. Resman-Targoff,et al.  Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. , 2010, The American journal of managed care.

[12]  A. Zinsmeister,et al.  Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. , 2010, Gastroenterology.

[13]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[14]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[15]  A. Ananthakrishnan,et al.  Editorial: Improved Efficacy of Biological Maintenance Therapy in “Early” Compared With “Late” Crohn's Disease: Strike While the Iron Is Hot With Anti-TNF Agents? , 2010, The American Journal of Gastroenterology.

[16]  J. Schölmerich,et al.  Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data , 2010, The American Journal of Gastroenterology.

[17]  P. Rutgeerts,et al.  T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND , 2010 .

[18]  J. Chao,et al.  S1031 Crohn's Disease Mucosal Healing in Adalimumab-Treated Patients is Affected by Disease Duration: Results From Extend , 2010 .

[19]  L. Peyrin-Biroulet,et al.  Early Crohn disease: a proposed definition for use in disease-modification trials , 2010, Gut.

[20]  L. Peyrin-Biroulet,et al.  The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.

[21]  A. Cieza,et al.  Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health , 2010, Inflammatory bowel diseases.

[22]  G. Kingsley,et al.  A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. , 2010, Rheumatology.

[23]  D. Goodin,et al.  Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode , 2009, Multiple sclerosis.

[24]  F. Cominelli.  Early and late gut immune responses in IBD. , 2008, Journal of pediatric gastroenterology and nutrition.

[25]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[26]  A. Levine,et al.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease , 2007, Gut.

[27]  S. Schreiber,et al.  P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm , 2007 .

[28]  K. Ley,et al.  GASTROENTEROLOGY 2006;131:1518–1529 Antibody Blockade of CCL25/CCR9 Ameliorates Early but not Late Chronic , 2022 .

[29]  S. Dorn.  Predictors of Crohn's disease. , 2006, Gastroenterology.

[30]  A. Lapidus.  Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. , 2006, World journal of gastroenterology.

[31]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[32]  F. Cominelli,et al.  Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. , 2005, Gastroenterology.

[33]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[34]  P. Lionetti,et al.  Response to infliximab is related to disease duration in paediatric Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[35]  P. Ros,et al.  Bowel obstruction revealed by multidetector CT. , 2002, AJR. American journal of roentgenology.

[36]  A. Zinsmeister,et al.  The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. , 2002, Gastroenterology.

[37]  J. Willis,et al.  Distinct inflammatory mechanisms mediate early versus late colitis in mice. , 2002, Gastroenterology.

[38]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[39]  G. Comi.  Why treat early multiple sclerosis patients? , 2000, Current opinion in neurology.

[40]  P. Desreumaux,et al.  Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. , 1997, Gastroenterology.

[41]  T. Barloon,et al.  CT diagnosis of small-bowel obstruction: efficacy in 60 patients. , 1992, AJR. American journal of roentgenology.

[42]  J Y Mary,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[43]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[44]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.